UTIBRON
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1,257 | 15 | 0 |
| 2019 | $3,029 | 15 | 0 |
| 2018 | $544,752 | 5,582 | 2,833 |
| 2017 | $4.1M | 54,199 | 15,134 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.8M | 1,223 | 60.6% |
| Food and Beverage | $796,956 | 47,899 | 17.0% |
| Travel and Lodging | $651,655 | 3,363 | 13.9% |
| Unspecified | $358,102 | 123 | 7.6% |
| Consulting Fee | $24,673 | 7 | 0.5% |
| Education | $19,638 | 7,196 | 0.4% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Novartis Pharmaceuticals Corporation | $346,822 | 0 |
| A 12 WEEK TREATMENT MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF QVA149 INDACATEROL MALEATE AND OR GLYCOPYRRONIUM BROMIDE IN COPD PATIENTS WITH MODERATE TO SEVERE AIRFLOW LIMITATION | Novartis Pharmaceuticals Corporation | $6,993 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONA | Novartis Pharmaceuticals Corporation | $4,286 | 0 |
Top Doctors Receiving Payments for UTIBRON — Page 645
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Adult Medicine | Forestdale, AL | $2.69 | 1 |
| , MD | Pulmonary Disease | Allentown, PA | $2.69 | 1 |
| , M.D | Specialist | Sumter, SC | $2.69 | 1 |
| , M.D | Internal Medicine | Leesburg, FL | $2.69 | 1 |
| , MD | Family Medicine | Guntersville, AL | $2.69 | 1 |
| , M.D | Family Medicine | Gadsden, AL | $2.69 | 1 |
| , MD | Family Medicine | Phila, PA | $2.69 | 1 |
| , MD | Internal Medicine | Marlborough, MA | $2.69 | 1 |
| , M.D | Family Medicine | Alexandria, KY | $2.69 | 1 |
| , MD | Pulmonary Disease | Brooklyn, NY | $2.69 | 1 |
| , MD | Family Medicine | Darlington, SC | $2.69 | 1 |
| , MD | Internal Medicine | Purcellville, VA | $2.69 | 1 |
| , MD | Allergy & Immunology | Charlotte, NC | $2.69 | 1 |
| , MD | Specialist | Abilene, TX | $2.69 | 1 |
| , M.D | Family Medicine | Niles, MI | $2.69 | 1 |
| , MD | Internal Medicine | Las Vegas, NV | $2.69 | 1 |
| , M.D | Pulmonary Disease | Newark, NJ | $2.69 | 1 |
| Ahmer Hussain | Emergency Medicine | Poteau, OK | $2.69 | 1 |
| , MD | Internal Medicine | Scottsboro, AL | $2.69 | 1 |
| , M.D | Family Medicine | Evansville, IN | $2.69 | 1 |
| , MD | Family Medicine | Lakeland, FL | $2.69 | 1 |
| , DO | Internal Medicine | Westland, MI | $2.69 | 1 |
| , M.D | Hospitalist | Racine, WI | $2.69 | 1 |
| , M.D | Critical Care Medicine | Fountain Hill, PA | $2.69 | 1 |
| , MD | Family Medicine | Whitesboro, NY | $2.69 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.7M
- Total Doctors 16,232
- Transactions 59,811
About UTIBRON
UTIBRON is a drug associated with $4.7M in payments to 16,232 healthcare providers, recorded across 59,811 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2020. In 2020, $1,257 was paid across 15 transactions to 0 doctors.
The most common payment nature for UTIBRON is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.8M, 60.6% of total).
UTIBRON is associated with 3 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE" ($346,822).